BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 1709658)

  • 1. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
    White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
    J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
    Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
    J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
    Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
    Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of vascularity in nodular melanoma and Spitz's nevus.
    Binder M; Steiner A; Mossbacher U; Hunegnaw M; Wolff K; Pehamberger H
    J Cutan Pathol; 1997 May; 24(5):272-7. PubMed ID: 9194579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigens associated with tumor progression in melanocytic neoplasia.
    Elder DE; Herlyn M
    Pigment Cell Res; 1992; Suppl 2():136-43. PubMed ID: 1409415
    [No Abstract]   [Full Text] [Related]  

  • 8. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
    Mehregan DR; Hamzavi I
    Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spitz's nevi with halo reaction: a histopathologic study of 17 cases.
    Harvell JD; Meehan SA; LeBoit PE
    J Cutan Pathol; 1997 Nov; 24(10):611-9. PubMed ID: 9449488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical studies of conjunctival nevi and melanomas.
    Jakobiec FA; Bhat P; Colby KA
    Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential reactivity of cells of the melanocytic lineage with four monoclonal antibodies against IFN-gamma inducible molecules.
    Vacca A; Frassanito A; Rimoldi D; Dammacco F; Carrel S
    Anticancer Res; 1992; 12(1):1-9. PubMed ID: 1348919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
    Yasuda H
    Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
    Paul E; Cochran AJ; Wen DR
    J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity.
    McNutt NS; Urmacher C; Hakimian J; Hoss DM; Lugo J
    J Cutan Pathol; 1995 Dec; 22(6):502-17. PubMed ID: 8835170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
    Nakanishi T; Hashimoto K
    Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
    Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen.
    Xu X; Azumi N; Skelton HG; Hearing VJ; Gersten DM
    Eur J Cancer; 1996 Jan; 32A(1):168-73. PubMed ID: 8695227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.